AU2010242415A1 - Flexible liposome of resveratrol and preparation method thereof - Google Patents

Flexible liposome of resveratrol and preparation method thereof Download PDF

Info

Publication number
AU2010242415A1
AU2010242415A1 AU2010242415A AU2010242415A AU2010242415A1 AU 2010242415 A1 AU2010242415 A1 AU 2010242415A1 AU 2010242415 A AU2010242415 A AU 2010242415A AU 2010242415 A AU2010242415 A AU 2010242415A AU 2010242415 A1 AU2010242415 A1 AU 2010242415A1
Authority
AU
Australia
Prior art keywords
lipid
resveratrol
preparation
flexible liposome
hydrated suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010242415A
Inventor
Jianming Chen
Ming Chen
Baoan Gao
Risheng Jin
Huiliang Li
Luo LV
Qing Shi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Jahwa United Co Ltd
Original Assignee
Shanghai Jahwa United Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jahwa United Co Ltd filed Critical Shanghai Jahwa United Co Ltd
Publication of AU2010242415A1 publication Critical patent/AU2010242415A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14Liposomes; Vesicles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/347Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39Derivatives containing from 2 to 10 oxyalkylene groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55Phosphorus compounds
    • A61K8/553Phospholipids, e.g. lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86Polyethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/18Antioxidants, e.g. antiradicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

A flexible liposome of resveratrol and the preparation method thereof are disclosed. The liposome comprises 0.5-10 wt% of resveratrol, 0.5-10 wt% of phospholipid and 0.1-30 wt% of flexible agent based on the total weight of the liposome.

Description

A resveratrol flexible liposome and the preparation method thereof Technical Field s The present invention relates to the cosmetic field, especially to a resveratrol flexible liposome and the preparation method thereof. Background to Resveratrol with its chemical name being 3,4,5-trihydroxystilbence, mainly exists in plants such as grap, polygonum cuspidatum, peanut, clover, mulberry, gnetum montanum, maackia amurensis, etc. It is a non-flavonoid polyphenolic compound having stilbene structure and has two isomers, i.e., cis and trans isomers. In nature, it mainly exists as trans form. 15 It has been proved that the resveratrol has good anti-aging effect and is identified as one of the most effective anti-aging substance. The mechanism of action consists in its abilities to scavenge the free radical in vivo, activate the function factors in vivo, promote and keep the proper metabolism in vivo, as well as harmonize the internal and 20 external secretion. The free radical-scavenging effect of the resveratrol makes it become a good natural antioxidant and suitable to be used as anti-aging agent. In addition, the anti-inflammatory and bactericidal effects of the resveratrol are highly suitable for treating and getting rid of skin acne and herpes etc. Additionally, the resveratrol also has the effects of keeping the skin moisture and protecting the skin 25 from ultraviolet radiation. Therefore, the resveratrol has a wide range of applications in the cosmetic field. However, the resveratrol is slightly soluble in water and has a poor biological compatibility, thus it is difficult to permeate the skin and is not suiable to make into hydrophilic cosmetics. In addition, the resveratrol is also extremely easy to photolysis. Therefore the above properties of the resveratrol limit its application in I 1111072-AU the cosmetic field. Based on long-term research, the inventor has found that it is possible to increase the skin penetration of the resveratrol thus to increase the skin absorption of resveratrol by making the resveratrol into flexible liposome. Meanwhile, making the resveratrol 5 into flexible liposome can also reduce the photolysis of the resveratrol and increase its stability. Invention Details 10 The technical problem underlying the invention is to provide a resveratrol flexible liposome with good transdermal absorption property. The resveratrol flexible liposome of the present invention comprise the following components with respect to the weight of the liposome: between 0.1 and 10% of the 15 resveratrol, between 0.5 and 10% of phospholipid and between 0.1 and 30% of softener. Preferably, the resveratrol is present in an amount of between 0.1 and 7% by weight, the phospholipid is present in an amount of between 0.5 and 8% by weight, 20 and the softener is present in an amount of between 0.1 and 20% by weight. More preferably, the resveratrol is present in an amount of between 0.5 and 5% by weight, the phospholipid is present in an amount of between I and 5% by weight, and the softener is present in an amount of between 1 and 10% by weight. 25 The resveratrol flexible liposome of the present invention may further comprise a suitable amount of antioxidant, preservative and stabilizer. One skilled in the art can easily determine said "suitable amount" according to the specific kinds of the selected antioxidant, preservative and stabilizer. 2 1111072-AU Preferably, the stabilizer is present in an amount of greater than 0 and less than or equal to 15% by weight, the antioxidant is present in an amount of between 0.005 and 0.5% by weight, and the preservative is present in an amount of between 0.005 and 5 0.5% by weight. More preferably, the stabilizer is present in an amount of greater than 0 and less than or equal to 10% by weight. 10 The phospholipid used in the resveratrol flexible liposome of the present invention may be one or more selected from the group consisting of soybean lecithin, egg yolk lecithin, distearoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, and dimyristoyl phosphatidylcholine. Preferably, the phospholipid used in the resveratrol flexible liposome of the present invention is one or more selected from the group 15 consisting of soybean lecithin and egg yolk lecithin. The softener may be one or more selected from the group consisting of Tween 80, cholic acid, sodium cholate, sodium deoxycholate, Span 80, polyoxyethylene (2) cetyl ether, propylene glycol and absolute ethanol. Preferably, the softener is one or more 20 selected from the group consisting of sodium cholate, Tween 80, propylene glycol and absolute ethanol. The stabilizer may be one or more selected from the group consisting of dicetyl phosphate, stigmasterol, sitosterol, cermaide, oleic acid, sodium oleate, 25 glycerylmonooleate, glyceryl caprylate, glyceryl caprate, caprylic/capric triglyceride and poloxamer. Preferably, the stabilizer is one or more selected from the group consisting of dicetyl phosphate, caprylic/capric triglyceride and poloxamer. The antioxidant may be one or more selected from the group consisting of vitamin 3 1111072-AU E, butylated hydroxyanisole, butylated hydroxytoluene, propyl gallate, vitamin C, sodium pyrosulfite and ethylenediamine tetraacetic acid. Preferably, the antioxidant is one or more selected from the group consisting of vitamin E, vitamin C, and sodium pyrosulfite. 5 The preservative may be one or more selected from the group consisting of ethyl p-hydroxybenzoate, propyl p-hydroxybenzoate and benzalkonium chloride. Preferably, the preservative is one or more selected from the group consisting of ethyl p-hydroxybenzoate and propyl p-hydroxybenzoate. 10 The present invention also provides a method for preparing a resveratrol flexible liposome, comprising the following steps in turn: (1) Preparation of a lipid solution: mixing the pharmaceutical active ingredient, i.e. resveratrol, phospholipid and a lipid soluble softener, adding the mixture into a suitable 15 organic solvent, and dissolving the mixture by heating at a temperature of 50-100OC; (2) preparation of a lipid hydrated suspension: placing the lipid solution in a rotatory evaporator, and volatilizing the organic solvent via rotary film evaporation at a temperature of 50-85 0 Cuntil a lipid film is formed on the bottom of the evaporator, then adding water for hydration to form a lipid hydrated suspension; 20 (3) subjecting the lipid hydrated suspension to one or more technical processes selected from homogenization, ultrasonic treatment and shearing to obtain a resveratrol flexible liposome. The above preparation method can further comprises: in preparation of the lipid 25 hydrated suspension of step (2), after the formation of the lipid film on the bottom of the evaporator, adding an aqueous solution comprising a water soluble softener for hydration to form the lipid hydrated suspension. The present invention also provides another method for preparing a resveratrol 4 1111072-AU flexible liposome, comprising the following steps in turn: (1) preparation of a lipid solution: mixing the pharmaceutical active ingredient, i.e. resveratrol and phospholipid, adding the mixture into a suitable organic solvent, and dissolving the mixture by heating at a temperature of 50-1OOC; 5 (2) preparation of a lipid hydrated suspension: placing the lipid solution in a rotatory evaporator, and volatilizing the organic solvent via rotary film evaporation at a temperature of 50-85 0 Cuntil a lipid film is formed on the bottom of the evaporator, then adding an aqueous solution comprising a water soluble softener for hydration to form a lipid hydrated suspension; 10 (3) subjecting the lipid hydrated suspension to one or more common technical processes selected from homogenization, ultrasonic treatment and shearing to obtain a resveratrol flexible liposome. The present invention also provides another method for preparing a resveratrol 15 flexible liposome, comprising the following steps in turn: (1) preparation of a lipid solution: mixing the pharmaceutical active ingredient, i.e. resveratrol, phospholipid and a lipid soluble softener, and melting the mixture by heating at a temperature of 50-1OO0OC; (2) preparation of a lipid hydrated suspension: dispersing the lipid solution directly 20 into the water of a temperature of 50-85'C to form a lipid hydrated suspension; (3) subjecting the lipid hydrated suspension to one or more technical processes selected from homogenization, ultrasonic treatment and shearing to obtain a resveratrol flexible liposome. 25 The above preparation method can further comprises: in preparation of the lipid hydrated suspension of step (2), adding the lipid solution directly into an aqueous solution comprising a water soluble softener of a temperature of 50-85'C for hydration to form the lipid hydrated suspension. 5 1111072-AU The present invention also provides another method for preparing a resveratrol flexible liposome, comprising the following steps in turn: (1) preparation of a lipid solution: mixing the pharmaceutical active ingredient, i.e. resveratrol and phospholipid, and melting the mixture by heating at a temperature of 5 50-100'C; (2) preparation of a lipid hydrated suspension: dispersing the lipid solution directly into an aqueous solution comprising a water soluble softener of a temperature of 50-85'C to form a lipid hydrated suspension; (3) subjecting the lipid hydrated suspension to one or more technical processes 10 selected from homogenization, ultrasonic treatment and shearing to obtain a resveratrol flexible liposome. The term "suitable organic solvent" used in the above preparation methods means any organic solvent capable of dissolving the mixture obtained in step (1). One 15 skilled in the art can determine the specific organic solvent according to the substances used in the step (1). Said "suitable organic solvent" is preferably one or more selected from the group consisting of dichloromethane, chloroform, diethyl ether and methanol. All the above mentioned methods for preparing the resveratrol flexible liposome 20 can further comprise the following steps: in preparation of the lipid solution in step (1), one or more lipid soluble components selected from the stabilizer, antioxidant and preservative are mixed with the resveratrol and phospholipid, or with the resveratrol, phospholipid and a lipid 25 soluble softener to obtain the lipid solution; and/or in preparation of the lipid hydrated suspension in step (2), one or more water soluble components selected from the stabilizer, antioxidant and preservative are added with the water or an aqueous solution comprising a water soluble softener to obtain the 6 1111072-AU lipid hydrated suspension. The above steps which the methods can further comprise means that the lipid soluble component(s) is/are added during the preparation of the lipid solution in step 5 (1), and the water soluble component(s) is/are added during the preparation of the lipid hydrated suspension of step (2), depending on the solubility of the selected stabilizer, antioxidant and preservative. The resveratrol flexible liposome of the present invention can be used as a part of 1 o a cosmetic formulation for the preparation of the cosmetic formulation in any suitable form such as emulsion, cream, oil, lotion, rod, gel and aerosol, and applied to the skin surface via a common method. In addition to the advantages of a conventional resveratrol liposome, the 15 resveratrol flexible liposome of the present invention is also highly flexible and has high penetrability, thus resulting in increased transdermal absorption of the active ingredient. It has been proved that the resveratrol flexible liposome of the present invention 20 has a greater deformability than a conventional resveratrol liposome by 5 orders of magnitude. For example, the resveratrol flexible liposome having a mean particle size of 500nm can pass through a pore having a size of 1/5 of the liposome, with the diameter of the liposome before and after the process almost remaining unchanged. Such property of the resveratrol flexible liposome is derived from the heterogeneity of 25 the lipid membrane. This is because the softener with surface active effect is present in the lipid membrane, and the softener aggregates easily at the high winding area. Therefore during the deformation process, the surface energy (elastic energy) required to be overcome is greatly reduced, which results in high deformability of the resveratrol flexible liposome. 7 1111072-AU Furthermore, the resveratrol flexible liposome of the present invention also has high hydrophilicity, which makes it possible to penetrate the skin along the hydration gradient. Since the resveratrol flexible liposome has high deformability, when 5 subjected to sufficiently high stress, it can freely pass through the pore passage several times smaller than itself, thereby resulting in high penetration. When the resveratrol flexible liposome suspension is applied to the skin surface, with the continuous evaporation of the solvent, the high hydrophilicity allows it to penetrate into the skin by means of the hydration gradient (the skin's own unique property) gradually increasing o from the surface of the skin to deep tissue. Its high deformability can ensure a successful penetration. However, the conventional resveratrol liposome still remains on the skin surface until dehydration and fusion due to lack of deformability. Brief Description of the Drawings 15 Fig. 1 shows curves of the accumulated amount of penetration per unit area, of the flexible liposome of the present invention and of the conventional liposome (X, n=6). Embodiment of the Present Invention 20 Further explanation of this invention with reference to Examples is given below. The Examples shall not be construed as a limitation on the scope of the invention in any way. 25 Example 1 1.2g resveratrol, 3g soybean lecithin and O.Olg vitamin E were mixed in an eggplant shaped bottle and dissolved with 30ml chloroform by heating at 450C to obtain a lipid solution; then the organic solvent was volatilized via rotation at 55*Cto form a lipid film; then 94.5g distilled water of 600C containing 0.2g sodium cholate, 8 1111072-AU 1.8g propylene glycol and 0.015g propyl p-hydroxybenzoate was added for hydrateion to form a lipid hydrated suspension; said lipid hydrated suspension was subjected to high pressure homogeneous emulsification to obtain the resveratrol flexible liposome. 5 Example 2 0.3g resveratrol, 0.8g soybean lecithin, 0.0 lg butylated hydroxyanisole and 1.Og glycerylmonooleate were mixed in an eggplant shaped bottle and melted by heating at 1000C to obtain a lipid solution; then the lipid solution was dispersed in 97.4g distilled water of 80'C containing 0.4g Tween 80, 0.015g sodium pyrosulfite and 0.Olg ethyl to p-hydroxybenzoate to form a lipid hydrated suspension; said lipid hydrated suspension was subjected to high pressure homogeneous emulsification to obtain the resveratrol flexible liposome. Example 3 15 1.2g resveratrol, 3g soybean lecithin, 12g propylene glycol, 1Og caprylic/capric triglyceride, 3g dicetyl phosphate and 0.02g butylated hydroxytoluene were mixed in an eggplant shaped bottle and melted by heating at 950C to obtain a lipid solution; then the lipid solution was dispersed in 58.8g distilled water of 800C containing 12g Tween 80, 0.008g ethylenediamine tetraacetic acid and 0.005g benzalkonium chloride to form 20 a lipid hydrated suspension; said lipid hydrated suspension was subjected to high pressure homogeneous emulsification to obtain the resveratrol flexible liposome. Example 4 2g resveratrol, 4g egg yolk lecithin, 3g stigmasterol and 0.006g propyl gallate 25 were mixed and dissolved with 8ml absolute ethanol by heating at 600C to obtain a lipid solution; then the lipid solution was dispersed in 82.7g distilled water of 60*C containing 0.2g sodium cholate, 0.8g propylene glycol, 0.015g ethyl p-hydroxybenzoate and 0.01g propyl p-hydroxybenzoate to form a lipid hydrated suspension; said lipid hydrated suspension was subjected to shear and high pressure 9 1111072-AU homogeneous emulsification to obtain the resveratrol flexible liposome. Example 5 3g resveratrol, 3g soybean lecithin, 2g egg yolk lecithin, 4g Span 80, 2.7g 5 polyoxyethylene (2) cetyl ether, 0.3g cholic acid, 6g sitosterol and 0.008g vitamin E were mixed and melted by heating at 780C, then 78.96g distilled water of 600C containing 0.03g sodium pyrosulfite and 0.015g ethyl p-hydroxybenzoate was added for hydration to form a lipid hydrated suspension; said lipid hydrated suspension was subjected to ultrasonic emulsification to obtain the resveratrol flexible liposome. 10 Example 6 4g resveratrol, 1.6g distearoyl phosphatidylcholine, 4g dipalmitoyl phosphatidylcholine, 0. lg cholic acid, 3.9g absolute ethanol and 9g glyceryl caprylate were mixed in an eggplant shaped bottle and melted by heating at 85'C to obtain a 15 lipid solution; then the lipid solution was dispersed in 71.36g distilled water of 800C containing 6g Tween 80, 0.03g sodium pyrosulfite and 0.005g benzalkonium chloride to form the lipid hydrated suspension; said lipid hydrated suspension was subjected to shear emulsification to obtain the resveratrol flexible liposome. 20 Example 7 4.7g resveratrol, 9g dimyristoyl phosphatidylcholine, 6g cholic acid, 4g glyceryl caprate, 3g dicetyl phosphate and 0.015g vitamin E were mixed and dissolved with 5ml absolute ethanol by heating at 750C to obtain a lipid solution; then the lipid solution was dispersed in 70.27g distilled water of 750C containing 0.015g propyl 25 p-hydroxybenzoate for hydration to form a lipid hydrated suspension; said lipid hydrated suspension was subjected to high pressure homogeneous emulsification to obtain the resveratrol flexible liposome. Example 8 10 1111072-AU 6g resveratrol, 7.2g egg yolk lecithin, 3g sitosterol, 3.8g cermaide and 1.2g oleic acid were mixed and dissolved with 10ml absolute ethanol by heating at 800C to obtain a lipid solution; then the lipid solution was dispersed in 73.8g distilled water of 800C containing 1.3g sodium deoxycholate, 3.7g propylene glycol, 0.005g vitamin C, 5 0.04g sodium pyrosulfite and 0.006g benzalkonium chloride for hydration to form a lipid hydrated suspension; said lipid hydrated suspension was subjected to high pressure homogeneous emulsification to obtain the resveratrol flexible liposome. Example 9 10 7g resveratrol, 8g soybean lecithin, 4g cholic acid, 4g polyoxyethylene (2) cetyl ether, 12g glyceryl caprylate and 3g poloxamer were mixed and melted by heating at 70C to obtain a lipid solution; then the lipid solution was dispersed in 53.97g distilled water of 70'C containing 8g Tween 80, 0.015g vitamin C and 0.Olg ethyl p-hydroxybenzoate to form a lipid hydrated suspension; said lipid hydrated suspension 15 was subjected to shear emulsification and ultrasonic emulsification to obtain the resveratrol flexible liposome. Example 10 9.5g resveratrol, 8g soybean lecithin, 2g dipalmitoyl phosphatidylcholine, 13g 20 caprylic/capric triglyceride, 4g oleic acid and 0.05g butylated hydroxytoluene were mixed and melted by heating at 900C to obtain a lipid solution; then the lipid solution was dispersed in 49.48g distilled water of 70'C containing 0.2g sodium cholate, 3.8g Tween 80, 1Og propylene glycol, 0.01g ethyl p-hydroxybenzoate and 0.015g propyl p-hydroxybenzoate to form a lipid hydrated suspension; said lipid hydrated suspension 25 was subjected to shear emulsification to obtain the resveratrol flexible liposome. Example I1 1.5g resveratrol, 4.8g egg yolk lecithin, 2g polyoxyethylene (2) cetyl ether and 4g dicetyl phosphate were mixed in an eggplant shaped bottle and dissolved with 25ml I1 1111072-AU dichloromethane by heating at 600C to obtain a lipid solution; then the organic solvent was volatilized via rotation at 6 0 Cto form a lipid film; 85.67g distilled water of 600C containing 2g sodium cholate, 0.03g sodium pyrosulfite and 0.008g benzalkonium chloride was added for hydration to form a lipid hydrated suspension; said lipid 5 hydrated suspension was subjected to high pressure homogeneous emulsification to obtain the resveratrol flexible liposome. Example 12 1 g resveratrol and 2.5g egg yolk lecithin were mixed in an eggplant shaped bottle 10 and dissolved with 5ml absolute ethanol by heating at 580C to obtain a lipid solution; then 89.47g distilled water of 580C containing 3g Tween 80, 1 g sodium cholate, 0.02g vitamin C and 0.01 g ethyl p-hydroxybenzoate was added for hydration to form a lipid hydrated suspension; said lipid hydrated suspension was subjected to high pressure homogeneous emulsification to obtain the resveratrol flexible liposome. 15 Example 13 2g resveratrol, 3.3g soybean lecithin and 0.05g caprylic/capric triglyceride were mixed in an eggplant shaped bottle and dissolved with 20ml chloroform by heating at 55 C to obtain a lipid solution; then the organic solvent was volatilized via rotation at 20 6 0 *Cto form a lipid film; 92.37g distilled water of 550C containing 0.lg sodium cholate, 1.1g propylene glycol, 0.02g vitamin C and 0.015g ethyl p-hydroxybenzoate was added t for hydration to form a lipid hydrated suspension; said lipid hydrated suspension was subjected to high pressure homogeneous emulsification to obtain the resveratrol flexible liposome. 25 Example 14 3g resveratrol, 4.5g soybean lecithin, 3g dicetyl phosphate and 4g caprylic/capric triglyceride were mixed and dissolved with 6ml absolute ethanol by heating at 800C to obtain a lipid solution; then the lipid solution was dispersed in 79.47g distilled water 12 1111072-AU of 800C containing 4g Tween 80, 2g propylene glycol, 0.03g sodium pyrosulfite and 0.008g benzalkonium chloride to form the lipid hydrated suspension; said lipid hydrated suspension was subjected to high pressure homogeneous emulsification to obtain the resveratrol flexible liposome. 5 Example 15 4.5g resveratrol, 5g soybean lecithin, 3g dicetyl phosphate, 5g caprylic/capric triglyceride and 0.02g vitamin E were mixed and dissolved with 7ml absolute ethanol by heating at 75'C to obtain the lipid solution; then the lipid solution was dispersed in to 73.46g distilled water of 75 0C containing 2g propylene glycol, 0.Olg ethyl p-hydroxybenzoate and 0.01 5g propyl p-hydroxybenzoate for hydration to form a lipid hydrated suspension; said lipid hydrated suspension was subjected to high speed shear emulsification to obtain the resveratrol flexible liposome. 15 Example 16 1.2g resveratrol, 3.5g soybean lecithin, 3g dicetyl phosphate, 2g caprylic/capric triglyceride and 0.008g butylated hydroxytoluene were mixed and dissolved with 6ml absolute ethanol by heating at 680C to obtain a lipid solution; then the lipid solution was dispersed in 80.3g distilled water of 700C containing 7g Tween 80, 3g propylene 20 glycol, 0.04g benzalkonium chloride for hydration to form a lipid hydrated suspension; said lipid hydrated suspension was subjected to ultrasonic emulsification to obtain the resveratrol flexible liposome. Example 17 25 1.8g resveratrol, 4g soybean lecithin, 3g dicetyl phosphate and 4g poloxamer were mixed and melted by heating at 80'C to obtain a lipid solution; then the lipid solution was dispersed in 81.2g distilled water of 800C containing 1g sodium cholate, 6g propylene glycol, 0.04g sodium pyrosulfite and 0.Og ethyl p-hydroxybenzoate for hydration to form a lipid hydrated suspension; said lipid hydrated suspension was 13 1111072-AU subjected to high pressure homogeneous emulsification to obtain the resveratrol flexible liposome. Example 18 5 Ig resveratrol, 2.5g soybean lecithin, 4g dicetyl phosphate and 0.02g vitamin E were mixed in an eggplant shaped bottle and dissolved with 22ml chloroform by heating at 550C to obtain a lipid solution; then the organic solvent was volatilized via rotation at 60*Cto form a lipid film; 87.42g distilled water of 600C containing 2g sodium cholate, 3g propylene glycol, 0.04g sodium pyrosulfite and 0.02g propyl 1o p-hydroxybenzoate was added for hydration to form a lipid hydrated suspension; said lipid hydrated suspension was subjected to high pressure homogeneous emulsification to obtain the resveratrol flexible liposome. Example 19 is 2g resveratrol, 2g soybean lecithin, 2g egg yolk lecithin, 3g polyoxyethylene (2) cetyl ether, 3g dicetyl phosphate and 0.05g propyl gallate were mixed in an eggplant shaped bottle and dissolved with 5ml absolute ethanol by heating at 800C to obtain a lipid solution; then the organic solvent was volatilized via rotation at 80 Cto form a lipid film; 82.9g distilled water of 80 C containing 5g Tween 80 and 0.04g 20 benzalkonium chloride was added for hydration to form a lipid hydrated suspension; said lipid hydrated suspension was subjected to high pressure homogeneous emulsification to obtain the resveratrol flexible liposome. Example 20 25 5g resveratrol, 5g egg yolk lecithin, 7g Span 80, 2g dicetyl phosphate and 8g caprylic/capric triglyceride were mixed in an eggplant shaped bottle and dissolved with 35ml chloroform by heating at 600C to obtain a lipid solution; then the organic solvent was volatilized via rotation at 55 0 Cto form a lipid film; 69.96g distilled water of 55'C containing 3g sodium deoxycholate, 0.02g sodium pyrosulfite and 0.02g propyl 14 1111072-AU p-hydroxybenzoate was added for hydration to form a lipid hydrated suspension; said lipid hydrated suspension was subjected to high pressure homogeneous emulsification to obtain the resveratrol flexible liposome. 5 Example 21 1.5g resveratrol and 4.2g soybean lecithin were mixed in an eggplant shaped bottle and dissolved with 22ml dichloromethane by heating at 600C to obtain a lipid solution; then the organic solvent is volatilized via rotation at 60 0 Cto form a lipid film; 86.23g distilled water of 700C containing 2g sodium cholate, 6g propylene glycol, 10 0.05g vitamin C and 0.02g ethyl p-hydroxybenzoate was added for hydration to form a lipid hydrated suspension; said lipid hydrated suspension was subjected to high pressure homogeneous emulsification to obtain the resveratrol flexible liposome. Comparative Examples 15 In order to better understand the advantages of the resveratrol flexible liposome of the present invention, a comparison between the resveratrol flexible liposome of the present invention and the conventional resveratrol liposome was conducted by the following experiments using in vitro transdermal test and deformability test. 20 The resveratrol flexible liposome prepared by Example 1 was used as the test sample. The conventional resveratrol liposome was prepared by the following method: 25 1.2g resveratrol, 3g soybean lecithin and 0.2g cholesterol were mixed in an eggplant shaped bottle and dissolved with a suitable amount of chloroform by heating at 450C to obtain a lipid solution; then the organic solvent was volatilized via rotation at 55'Cto form a lipid film; 95.6g distilled water of 60'C was added for hydration to form a lipid hydrated suspension; said lipid hydrated suspension was subjected to high pressure 15 1111072-AU homogeneous emulsification to obtain the conventional resveratrol liposome as a control. I. In vitro transdermal test 5 1. Material and method 1.1. The preparation of the in vitro mouse skin 6 female naked mice (purchased from the experimental animal centre of the Second Military Medical University) were killed by cervical dislocation, the back skin was taken, from which the subcutaneous tissue was removed, and was washed with 10 normal saline before being frozen until use. 1.2. Diffuse experimental device and method By using modified Franz diffusion cells, the mouse skin was fixed between the supply chamber and the acceptance chamber with stratum corneum facing the 15 supply chamber and dermis facing the acceptance chamber. The dermis was kept close contact with the acceptance solution that is normal saline. The contact area between the skin and the acceptance solution was 1.0cm 2 , the volume of the acceptance solution was 4.2ml, and temperature of the thermostatic water bath is 320. Each 1ml of the sample of the flexible liposome and the conventional 20 liposome was added to different supply chambers and evenly applied to the surface of the stratum corneum of the mouse skin. Under continuous agitation, 1ml acceptance solution was taken at 2h, 5h, 8h, 11 h, 14h, 17h, 20h and 24h after application of the liposomes, and filtrated through 0.45pm millipore filter, then stored at 4'C until the determination of the concentration of the resveratrol. At 25 the same time, the same amount of fresh blank acceptance solution at the same temperature was supplemented. The experimental process was conducted under protection from light in order to avoid the occurrence of the photolysis reaction of the resveratrol under the experiment condition. 16 1111072-AU 1.3. The determination of the accumulated amount of penetration per unit area Liquid phase condition: Agilent 1100 liquid chromatography, Agilent G1314A VWD detector, Agilent G1311A Type four-pumps, Agilent G1314A 5 VWD detector, Agilent LC1100 chromatographic data work station, Diamonsil C18 analytical column (5pt, 4.6mmx250mm), acetonitrile-0.2% glacial acetic acid (35:65) as the mobile phase, flow rate 1.Oml/min, detection wavelength 306nm, and column temperature 25*C. 10 Test method: iml of acceptance solution was filtrated through 0.45pm millipore filter, and subsequent filtrate was used as sample solution. A suitable amount of resveratrol (control) was weighed precisely and placed in a brown volumetric flask, then methanol was added to achieve a concentration of 50 Ig resveratrol per 1 ml solution. 1.Oml of solution was transferred precisely and 15 placed in a brown volumetric flask, then the normal saline was added to the calibration and homogenously mixed. The obtained solution was used as a control solution. Each 100ptl of the sample solution and the control solution was transferred precisely and injected into liquid chromatograph. The concentration of the resveratrol (Cn) was calculated by external standard method. 20 Calculation formula of the accumulated amount of penetration per unit area: Qn=( C n V + C v )/ s wherein Q, is the accumulated amount of penetration per unit area at time point n; Cn is the concentration measured at time point n; Ci is the concentration 25 measured at time point n-1; V is the volume of the acceptance solution; Vi is the volume of the sample; and S is the diffusion area. 1.4. Statistical method 17 1111072-AU The accumulated amount of penetration of the resveratrol (ng/cm 2 ) at different time point was calculated for the acceptance solution. All the obtained results were expressed in mean ± standard deviation ( x ±SD). The two groups of the results were compared by Student test. 5 2. Test results 2.1 The stability of the resveratrol in the normal saline A suitable amount of the resveratrol was weighed and placed in a brown volumetric flask, firstly dissolved in small amount of methanol and then diluted with 1o the normal saline to the calibration. The stability was examined by placing the sample in a water bath of 320C under protection from light. The result showed that the resveratrol is still quite stable after 24 hours under the condition of placing the sample in a water bath of 320C and protecting from light. The results are shown in table 1 (comparison of the peak area). 15 Table 1. The stability test of the resveratrol in the normal saline Time(h) 0 3 6 18 24 peak area 378.9 363.2 376.5 377.7 369.9 2.2 Accumulated amount of penetration 20 During the 24h of penetration, there was a significant difference between the accumulated amount of penetration of the resveratrol flexible liposome and of the conventional resveratrol liposome against the in vitro naked mouse skin. The accumulated amount of penetration of the resveratrol flexible liposome against the in vitro naked mouse skin is greater than that of the conventional resveratrol liposome 25 (P<0.05). The results are shown in table 2 and Fig. 1. Table 2. The accumulated amounts of penetration of the two resveratrol 18 1111072-AU liposomes against the in vitro naked mouse skin (ng/cm 2 , n-6) Penetration time(h) conventional liposome flexible liposome 2 3.87 ± 1.77 9.25±2.76 5 12.73 ±2.12 21.55 ± 2.85 8 52.48 ± 9.11 68.93 ± 8.69 11 139.80 ±20.71 205.13 ±32.95 14 345.35 ±60.61 655.4 ±110.92 17 618.38 ±90.03 1017.48± 132.58 20 829.13 ±74.1 1553.87± 170.78 24 1165.6 ±131.2 2039.08 ±323.19 3. Result s The in vitro transdermal test has shown that there was a significant difference between the accumulated amount of penetration of the resveratrol flexible liposome against the in vitro naked mouse skin and that of the conventional resveratrol liposome, and that the accumulated amount of penetration of the resveratrol flexible liposome against the in vitro naked mouse skin is greater than that of conventional resveratrol 10 liposome. H. Deformability test 1. Method The comparison between the resveratrol flexible liposome and the conventional 15 liposome in terms of their deformability to pass through the millipore filter with a pore diameter of 0.20pm were conducted under an external pressure of 0.2MPa. First, the rate (V water), at which the distilled water passes through the millipore filter with a pore diameter of 0.20gm, was measured, then the rates (Vransfersomes), at which the resveratrol flexible liposome and the conventional liposome pass through the millipore 20 filter with a pore diameter of 0.20pm were measured respectively. The relative 19 1111072-AU penetration rate was calculated by the following formula: P=Vtransfersomes/V water X 100 %. 2. Result 5 The resveratrol flexible liposome of the present invention has a p value of 88% while the conventional resveratrol liposome has a p value of 56%, under an external pressure of 0.2MIPa. 3. Conclution 10 This test has shown that the resveratrol flexible liposome of the present invention has a better deformability than the conventional resveratrol liposome. 20 1111072-AU

Claims (15)

  1. 2. The resveratrol flexible liposome according to claim 1, wherein the resveratrol 1o is present in an amount of between 0.1 and 7% by weight, the phospholipid is present in an amount of between 0.5 and 8% by weight, and the softener is present in an amount of between 0.1 and 20% by weight.
  2. 3. The resveratrol flexible liposome according to claim 2, wherein the resveratrol 15 is present in an amount of between 0.5 and 5% by weight, the phospholipid is present in an amount of between 1 and 5% by weight, and the softener is present in an amount of between 1 and 10% by weight.
  3. 4. The resveratrol flexible liposome according to claim 1, further comprising a 20 suitable amount of stabilizer, antioxidant and preservative.
  4. 5. The resveratrol flexible liposome according to claim 4, wherein the stabilizer is present in an amount of greater than 0 and less than or equal to 15% by weight, the antioxidant is present in an amount of between 0.005 and 0.5% by weight, and the 25 preservative is present in an amount of between 0.005 and 0.5% by weight.
  5. 6. The resveratrol flexible liposome according to claim 5, wherein the stabilizer is present in an amount of greater than 0 and less than or equal to 10% by weight. 21 1111072-AU
  6. 7. The resveratrol flexible liposome according to claim 4, wherein: the phospholipid is one or more selected from the group consisting of soybean lecithin, egg yolk lecithin, distearoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, and dimyristoyl phosphatidylcholine; 5 the softener is one or more selected from the group consisting of Tween 80, cholic acid, sodium cholate, sodium deoxycholate, Span 80, polyoxyethylene (2) cetyl ether, propylene glycol and absolute ethanol; the stabilizer is one or more selected from the group consisting of dicetyl phosphate, stigmasterol, sitosterol, cholesterol, cermaide, oleic acid, sodium oleate, 10 glyceryl monooleate, glyceryl caprylate, glyceryl caprate, caprylic/capric triglyceride and poloxamer; the antioxidant is one or more selected from the group consisting of vitamin E, butylated hydroxyanisole, butylated hydroxytoluene, propyl gallate, vitamin C, sodium pyrosulfite and ethylenediamine tetraacetic acid; and 15 the preservative is one or more selected from the group consisting of ethyl p-hydroxybenzoate, propyl p-hydroxybenzoate and benzalkonium chloride.
  7. 8. The resveratrol flexible liposome according to claim 7, wherein: the phospholipid is one or more selected from the group consisting of soybean 20 lecithin and egg yolk lecithin; the softener is one or more selected from the group consisting of Tween 80, sodium cholate, propylene glycol and absolute ethanol; the stabilizer is one or more selected from the group consisting of dicetyl phosphate, caprylic/capric triglyceride and poloxamer; 25 the antioxidant is one or more selected from the group consisting of vitamin E, vitamin C, and sodium pyrosulfite; and the preservative is one or more selected from the group consisting of ethyl p-hydroxybenzoate, and propyl p-hydroxybenzoate. 22 1111072-AU
  8. 9. A method for preparing the resveratrol flexible liposome according to claim 1, comprising the following steps in turn: (1) preparation of a lipid solution: mixing resveratrol, phospholipid and a lipid soluble softener, adding the mixture into a suitable organic solvent, and dissolving the 5 mixture by heating at a temperature of 50-100 C; (2) preparation of a lipid hydrated suspension: placing the lipid solution in a rotatory evaporator, and volatilizing the organic solvent via rotary film evaporation at a temperature of 50-85 0 Cuntil a lipid film is formed on the bottom of the evaporator, then adding water for hydration to form a lipid hydrated suspension; 1o (3) preparation of the flexible liposome: subjecting the lipid hydrated suspension to one or more technical processes selected from homogenization, ultrasonic treatment and shearing to obtain the resveratrol flexible liposome.
  9. 10. The method according to claim 9, wherein in preparation of the lipid hydrated 15 suspension of step (2), after the formation of the lipid film on the bottom of the evaporator, adding an aqueous solution comprising a water soluble softener for hydration to form the lipid hydrated suspension.
  10. 11. A method for preparing the resveratrol flexible liposome according to claim 1, 20 comprising the following steps in turn: (1) preparation of a lipid solution: mixing resveratrol and phospholipid, adding mixture into a suitable organic solvent, and dissolving the mixture by heating a temperature of 50-1 00 0 C; (2) preparation of a lipid hydrated suspension: placing the lipid solution in a 25 rotatory evaporator, and volatilizing the organic solvent via rotary film evaporation at a temperature of 50-85'Cuntil a lipid film is formed on the bottom of the evaporator, then adding an aqueous solution comprising a water soluble softener for hydration to form a lipid hydrated suspension; (3) preparation of the flexible liposome: subjecting the lipid hydrated suspension 23 1111072-AU to one or more technical processes selected from homogenization, ultrasonic treatment and shearing to obtain the resveratrol flexible liposome.
  11. 12. A method for preparing the resveratrol flexible liposome according to claim 1, s comprising the following steps in turn: (1) preparation of a lipid solution: mixing resveratrol, phospholipid and a lipid soluble softener, and melting the mixture by heating at a temperature of 50-100 OC; (2) preparation of a lipid hydrated suspension: dispersing the lipid solution directly into the water of a temperature of 50-85*C to form a lipid hydrated suspension; 10 (3) preparation of the flexible liposome: subjecting the lipid hydrated suspension to one or more technical processes selected from homogenization, ultrasonic treatment and shearing to obtain the resveratrol flexible liposome.
  12. 13. The method according to claim 12, wherein in preparation of the lipid hydrated 15 suspension of step (2), adding the lipid solution directly into an aqueous solution comprising a water soluble softener of a temperature of 50-85'C for hydration to form the lipid hydrated suspension.
  13. 14. A method for preparing the resveratrol flexible liposome according to claim 1, 20 comprising the following steps in turn: (1) preparation of a lipid solution: mixing resveratrol and phospholipid, and melting the mixture by heating at a temperature of 50-1 00 0 C; (2) preparation of a lipid hydrated suspension: dispersing the lipid solution directly into an aqueous solution comprising a water soluble softener of a temperature of 25 50-85*C to form a lipid hydrated suspension; (3) preparation of the flexible liposome: subjecting the lipid hydrated suspension to one or more technical processes selected from homogenization, ultrasonic treatment and shearing to obtain the resveratrol flexible liposome. 24 1111072-AU
  14. 15. The method according to any one of claims 9-14, wherein: in preparation of the lipid solution in step (1), a lipid soluble stabilizer and/or an antioxidant and/or a preservative are mixed with the resveratrol and phospholipid to obtain the lipid solution; or with the resveratrol, phospholipid and a lipid soluble 5 softener to obtain the lipid solution; and/or in preparation of the lipid hydrated suspension in step (2), a water soluble stabilizer, an antioxidant and a preservative are added with water to obtain the lipid hydrated suspension; or a water soluble stabilizer, an antioxidant and a preservative are added with an aqueous solution comprising a water soluble softener to obtain the lipid 1o hydrated suspension.
  15. 16. The method according to any one of claims 9-14, wherein the organic solvent used is one or more selected from the group consisting of dichloromethane, chloroform, diethyl ether and methanol. 15 25 1111072-AU
AU2010242415A 2009-04-29 2010-03-12 Flexible liposome of resveratrol and preparation method thereof Abandoned AU2010242415A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200910050247.3 2009-04-29
CN2009100502473A CN101874763A (en) 2009-04-29 2009-04-29 Resveratrol flexible liposome and preparation method thereof
PCT/CN2010/071011 WO2010124540A1 (en) 2009-04-29 2010-03-12 Flexible liposome of resveratrol and preparation method thereof

Publications (1)

Publication Number Publication Date
AU2010242415A1 true AU2010242415A1 (en) 2011-12-22

Family

ID=43017513

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010242415A Abandoned AU2010242415A1 (en) 2009-04-29 2010-03-12 Flexible liposome of resveratrol and preparation method thereof

Country Status (4)

Country Link
EP (1) EP2431023A4 (en)
CN (1) CN101874763A (en)
AU (1) AU2010242415A1 (en)
WO (1) WO2010124540A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102440958B (en) * 2011-11-29 2013-01-23 海南永田药物研究院有限公司 Ibuprofen sodium liposome solid preparation and preparation method thereof
ITRM20120267A1 (en) * 2012-06-08 2013-12-09 Antonio Chiarella MICRONIZABLE LIQUID FORMULATION FOR THERAPEUTIC TREATMENT OF ACNE AND OTHER RELATED SKIN PATHOLOGIES
WO2014085914A1 (en) * 2012-12-06 2014-06-12 Misudan Enterprises Inc. Topical liposome compositions containing phenolic anti-inflammatory agents and their methods of preparation
CN103494772A (en) * 2013-09-29 2014-01-08 南京中医药大学 Compound phosphatide transfer body with high deformability and application thereof in preparing transdermal drug delivery preparation
EP2944202A1 (en) * 2014-05-14 2015-11-18 Lypo C AB A method for manufacturing a mixture of lypo-spheric vitamin C and a mixture of lypo-spheric vitamin C
CN104490636A (en) * 2014-12-12 2015-04-08 唯美度科技(北京)有限公司 External preparation using carnosine as active component and preparation method of external preparation
MX2018002461A (en) * 2015-08-28 2018-06-07 Caliway Biopharmaceuticals Co Ltd Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition.
CN105168007B (en) * 2015-09-18 2018-10-12 上海应用技术学院 A kind of preparation method of liposome
CN105213206B (en) * 2015-09-18 2018-10-12 上海应用技术学院 A kind of enoxolone liposome and preparation method thereof
CN105213207B (en) * 2015-09-23 2018-10-12 上海应用技术学院 A kind of non-phospholipid surfactants multiplet liposome and preparation method thereof
CN108721679B (en) * 2016-02-03 2020-11-20 唐山市博世德医疗器械有限公司 Anti-inflammatory and antibacterial medical dressing
DK3468535T3 (en) * 2016-06-14 2020-07-06 Aquanova Ag RESVERATROL SOLUBILIZATION PRODUCT FOR PHARMACOLOGICAL PURPOSES
KR102084672B1 (en) * 2016-09-28 2020-03-04 가부시키가이샤 만다무 Cosmetic composition
US20200030457A1 (en) * 2017-04-03 2020-01-30 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
CN107144696B (en) * 2017-06-05 2018-10-12 临沂大学 It is a kind of to be inlayed conducive to film enzyme and its enzyme of activity research-phosphatide microcapsule preparation method
CN109700671B (en) * 2018-02-13 2022-04-15 深圳高尚科美生物科技有限公司 Flexible liposome cosmetic containing active small molecular substance and preparation method thereof
CN109125302A (en) * 2018-10-09 2019-01-04 上海市杨浦区中心医院(同济大学附属杨浦医院) Application of resveratrol in medicine for treating bacterial pneumonia
CN111195230B (en) * 2018-11-19 2024-01-12 奥维嘉生物科技(北京)有限公司 Method for preparing flexible liposome
CN109481321B (en) * 2018-12-17 2022-05-24 广州市晨茜化工有限公司 Flexible tranexamic acid liposome capable of whitening skin and removing freckles as well as preparation method and application thereof
CN109528725B (en) * 2019-01-15 2021-01-15 华中科技大学 Nanometer composition containing diaminopyrimidine oxide and pyrrolidinyl diaminopyrimidine oxide, and preparation method and application thereof
CN110200829B (en) * 2019-05-17 2022-04-01 湖南人文科技学院 Resveratrol nano ethosome and preparation method and application thereof
WO2021089581A1 (en) * 2019-11-04 2021-05-14 Universitat Autonoma De Barcelona Tooth whitening composition
CN112137959A (en) * 2020-09-21 2020-12-29 王立强 Flexible nano liposome of astaxanthin and preparation method thereof
CN112057360A (en) * 2020-10-09 2020-12-11 王立强 Preparation of egg astaxanthin flexible nano liposome composition and makeup product
CN112807248B (en) * 2020-12-31 2022-03-22 海南大学 Coconut oil nanosphere and preparation method thereof
CN112773728A (en) * 2020-12-31 2021-05-11 江西科技师范大学 Compound of nano-encapsulated resveratrol, preparation method and application thereof
CN113509442A (en) * 2021-06-21 2021-10-19 浙江宜格企业管理集团有限公司 A liposome containing bakuchiol and its preparation method
CN113520938A (en) * 2021-06-25 2021-10-22 莆田市美肤莱化妆品有限公司 PH-targeted flexible nano-liposome with speckle removing effect and preparation method thereof
CN115607511B (en) * 2021-07-16 2024-05-31 中国科学院上海药物研究所 Resveratrol liposome, preparation method and application thereof
CN114288411A (en) * 2022-01-06 2022-04-08 王立强 Novel auxiliary material component capable of improving stability of flexible nano liposome and proportion thereof
HRP20220570A1 (en) * 2022-05-03 2023-11-10 PROTEKO d.o.o. Formulation of resveratrol-based functional cosmetic ingredient, procedure for its preparation and usage
CN114767738B (en) * 2022-05-20 2023-05-19 安徽中医药大学 Sanbai soup delivery body and preparation method thereof
CN115177535B (en) * 2022-05-27 2023-07-07 吉林省中鹿中医药产业(集团)有限公司 Deer skin collagen polypeptide liposome hydrogel, preparation method and application thereof
CN115068352B (en) * 2022-06-01 2023-10-20 吉林大学 Oil control polypeptide flexible liposome hydrogel and preparation method and application thereof
CN115998712B (en) * 2023-02-08 2024-06-21 吉林大学 Resveratrol nanosphere material and preparation method and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270780B1 (en) * 1997-07-25 2001-08-07 Chesebrough-Pond's Usa Co., Division Of Conopco Cosmetic compositions containing resveratrol
KR100521768B1 (en) * 2003-05-26 2005-10-17 엔프라니 주식회사 Cosmetic Compositions for a Skin Whitening
EP1726292A1 (en) * 2005-05-23 2006-11-29 Reckitt Benckiser (UK) LIMITED Composition comprising resveratrol and topical use thereof for reducing human hair growth
CN100453071C (en) * 2006-11-03 2009-01-21 李万忠 Oral resveratrol multi-phase liposome and preparation method thereof
CN101317819B (en) * 2007-06-05 2012-05-30 天津药物研究院 Rotigotine flexible liposome and transdermal drug administration formulation for hydrophilic substance

Also Published As

Publication number Publication date
CN101874763A (en) 2010-11-03
EP2431023A4 (en) 2012-11-21
EP2431023A1 (en) 2012-03-21
WO2010124540A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
AU2010242415A1 (en) Flexible liposome of resveratrol and preparation method thereof
Schlupp et al. Drug release and skin penetration from solid lipid nanoparticles and a base cream: a systematic approach from a comparison of three glucocorticoids
US20070082042A1 (en) Multiple-layered liposome and preparation method thereof
CN106420610B (en) A kind of ionic liquid micro emulsion and its application
KR102127022B1 (en) Oil/water-emulsion-type topical compositions containing a retinoid
CN112336649B (en) Preparation method and product of skin co-permeation carrier of ceramide and fat-soluble active substance
KR20130134532A (en) Multilayer liquid crystal vesicle for relieving skin irritation and for recovering skin barrier, and cosmetic composition comprising the same
KR20120115991A (en) Carrier composition
Zhou et al. Development of gliclazide ionic liquid and the transdermal patches: An effective and noninvasive sustained release formulation to achieve hypoglycemic effects
CN106361703A (en) Finasteride nano-liposome, gel and preparation method thereof
KR20200028547A (en) Transparent liposome composition containing centella asiatica extract
JP2015518033A (en) O / W-emulsion type topical pharmaceutical composition containing retinoid
KR20090009054A (en) Cosmetic composition comprising nanovesicle vitatox which having the effect of anti-oxidation and the effect of anti- wrinkle around the eye
KR100511944B1 (en) Cosmetic composition comprising asiaticoside
US11730687B2 (en) Emulsion structure for enhancing skin absorption and method of preparing the same
KR20200049592A (en) Water-in-oil type cosmetic composition comprising nano liposome
CN101601652A (en) Momestasone furoate lipidosome cream
KR102013804B1 (en) Cosmetic composition comprising cubosome containing active ingredient
KR20130109282A (en) Water soluble caffeine and preparing method thereof
KR101787583B1 (en) Cosmetic composition comprising maackia amurensis extract having effect of skin wrinkle improvement and cosmetic using the same
Shokri et al. Zinc Oxide and Zinc Oxide nanoparticles as enhancers in topical pharmaceutical and cosmetic products
Esposito et al. Gelified reverse micellar dispersions as percutaneous formulations
DE102006040450B3 (en) Use of a composition for skin treatment after X-irradiation
CN115590818B (en) Thermosensitive nanoliposome capable of realizing stepped release of active substances and application thereof
KR20240057003A (en) Liquid crystal gel cosmetic composition comprising complex for promoting skin permeation

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application